W
William Thomas
Researcher at University of Minnesota
Publications - 165
Citations - 12621
William Thomas is an academic researcher from University of Minnesota. The author has contributed to research in topics: Diabetes mellitus & Insulin. The author has an hindex of 61, co-authored 163 publications receiving 11534 citations. Previous affiliations of William Thomas include Regions Hospital.
Papers
More filters
Journal ArticleDOI
β-Cell Function and the Development of Diabetes-Related Complications in the Diabetes Control and Complications Trial
TL;DR: Even modest levels of beta-cell activity at entry in the DCCT were associated with reduced incidences of retinopathy and nephropathy, and continuing C-peptide (insulin) secretion is important in avoiding hypoglycemia (the major complication of intensive diabetic therapy).
Journal ArticleDOI
Cystic Fibrosis–Related Diabetes: Current Trends in Prevalence, Incidence, and Mortality
TL;DR: It is believed that early diagnosis and aggressive treatment have played a major role in improving survival in patients with Cystic fibrosis and diabetes, and the gap in mortality between CF patients with and without diabetes has considerably narrowed.
Journal ArticleDOI
Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices
Sheri Crow,Ranjit John,Andrew J. Boyle,Sara J. Shumway,Kenneth Liao,Monica Colvin-Adams,Carol Toninato,Emil Missov,Marc R. Pritzker,Cindy M. Martin,Daniel J. Garry,William Thomas,Lyle D. Joyce +12 more
TL;DR: Patients with nonpulsatile left ventricular assist devices appear to have a higher rate of gastrointestinal bleeding events than do pulsatile left Ventricular assist device recipients.
Journal ArticleDOI
Concentrated oat β-glucan, a fermentable fiber, lowers serum cholesterol in hypercholesterolemic adults in a randomized controlled trial
Katie M Queenan,Maria L. Stewart,Kristen N Smith,William Thomas,R. Gary Fulcher,R. Gary Fulcher,Joanne L. Slavin +6 more
TL;DR: Six grams concentrated oat β-glucan per day for six weeks significantly reduced total and LDL cholesterol in subjects with elevated cholesterol, and the LDL cholesterol reduction was greater than the change in the control group.
Journal ArticleDOI
Acquired von Willebrand Syndrome in Continuous-Flow Ventricular Assist Device Recipients
Sheri Crow,Dong Chen,Carmelo A. Milano,William Thomas,Lyle D. Joyce,Valentino Piacentino,Riti Sharma,Jogin R. Wu,Gowthami M. Arepally,Dawn E. Bowles,Joseph G. Rogers,Nestor Villamizar-Ortiz +11 more
TL;DR: It is suggested that loss of HMW vWF multimers alone cannot predict bleeding risk, and further refinement of laboratory techniques and a larger follow-up is required to identify risk factors for bleeding in CF-LVAD recipients.